In the intensely competitive landscape of oncology, pharmaceutical and biotech companies need every advantage to maximize market penetration, optimize commercial strategy, and ensure treatment gets to the patients who need it most.
We provide actionable intelligence derived from the industry’s most comprehensive and timely lab data, empowering your commercial teams to achieve unprecedented precision and efficiency.
Oncology lab data is a goldmine of insights, but extracting its value is notoriously difficult. Commercial teams face a daunting array of obstacles: fragmented data sources, a lack of standardization, inconsistent data quality, and the sheer volume of information.
Prognos Health specializes in overcoming these challenges. We transform raw, unwieldy lab data into a strategic asset, providing the clean, standardized, and enriched information pharma and biotech need to drive commercial success.
Prognos Health offers a suite of solutions tailored to the critical needs of oncology commercial teams:
Access the industry's most extensive oncology data platform, integrating data from leading national reference labs, specialized cancer diagnostic labs, liquid biopsy providers, and more.
This platform provides unparalleled depth and breadth across a wide range of conditions, including:
Non-Small Cell Lung Cancer (NSCLC)
Multiple Myeloma (MMY)
Breast Cancer
Prostate Cancer
Colorectal Cancer (CRC)
Ovarian Cancer
Hematologic Malignancies
Integration, Harmonization, Enrichment: Our proprietary technology, including advanced ML/AI, cleanses, standardizes, and enriches raw lab data, ensuring its accuracy, consistency, and immediate usability for commercial applications.
Seize the Commercial Moment:
In the fast-paced oncology market, timing is everything.
Prognos delivers data with the speed commercial teams require to optimize engagement, outmaneuver competitors, and maximize product impact.
Capture the latest market dynamics and enable rapid response.
Balance speed and operational efficiency.
Gain a crucial competitive edge.
Target the right physicians with the right message at the right time.
Prognos data enables highly targeted campaigns, optimizing resource allocation and maximizing ROI.
Identify high-potential prescribers, segment the market based on data-driven insights, and personalize outreach strategies for maximum effectiveness.
Trigger timely interventions and guide sales teams with actionable intelligence, ensuring optimal engagement with key accounts.
Map the patient journey to identify critical intervention points, optimize market access strategies, and improve patient outcomes, all while maximizing commercial opportunities.
For companies developing therapies for rare oncological conditions, Prognos provides the ability to identify elusive patient populations, accelerating diagnosis and treatment.
A leading pharmaceutical company, launching a novel oncology therapy, needed to optimize their commercialization strategy. They sought to leverage detailed patient and physician data to refine segmentation, personalize messaging, and ensure a rapid and successful launch.
Prognos Health partnered with the company to provide a comprehensive data and analytics solution. This included:
Pre-launch market assessment and segmentation
Targeted HCP identification and profiling
Post-launch tracking of key performance indicators
Omnichannel campaign optimization
Prognos enabled the company to:
Accelerate time to peak sales
Improve sales force effectiveness
Optimize marketing spend
Achieve a faster and more successful product launch
Maximize the efficiency of sales and marketing efforts by precisely identifying the highest-potential physicians and patient populations.
Get to market faster and more effectively with data-driven insights that optimize launch strategy and execution.
Reduce wasted spend and maximize ROI by focusing resources on the most promising opportunities.
Outmaneuver competitors with timely, actionable intelligence that enables proactive decision-making.
Prognos Health's data solutions provide comprehensive coverage across the spectrum of oncological conditions, including:
Non-Small Cell Lung Cancer (NSCLC)
Multiple Myeloma (MM)
Acute Myelogenous Leukemia (AML)
Breast Cancer
Prostate Cancer
Colorectal Cancer (CRC)
Ovarian Cancer
Hematologic Malignancies
And many more
“Prognos data is the most consistent we are seeing across all of our data vendors and overall, the program is running very smoothly. We love to see how effectiveness changes over time from the VGCC test results and we cannot see that from other vendors.”
Rare Disease Pharma
Brand Marketing
“The Prognos Alerts program is, without doubt, the most impactful marketing lever that we can pull. It's better than any marketing campaign, segmentation, call plan, account strategy that we have used.”
Mid-tier Pharma
Brand Marketing
“We were thrilled with the new data and the additional 2,150 NPIs what were not in our current tables. This was a much bigger increase than we expected.”
Rare Disease Pharma
Marketing Director
“I must say that I am impressed with the cleanliness of the data, which columns are for numeric and non-numeric
results and the consistent units of measurement. I look forward to working with this data and aggregating it into our current deliverable.”
Top 10 Pharma
Commercial Analytics Director
Ready to transform your oncology commercial strategy with the power of Prognos Health data?
Contact us today to learn how we can drive your success.